Comparison Between Paclitaxel-Carboplatin and Paclitaxel-Cisplatin as a Combination Chemotherapy in Recurrent Ovarian Cancer.
- Author:
Hang Jo YOO
1
;
Yong Man KIM
;
Hea Rim LEE
;
Mi Kyung KIM
;
Dong Heon LEE
;
Jong Hyeok KIM
;
Young Tak KIM
;
Jung Eun MOK
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Recurrent ovarian cancer;
Paclitaxel-Carboplatin;
Paclitaxel-Cispaltin;
Chemotherapy
- MeSH:
Anemia;
Appointments and Schedules;
Arm;
Carboplatin;
Chungcheongnam-do;
Cisplatin;
Drug Therapy;
Drug Therapy, Combination*;
Fever;
Follow-Up Studies;
Gynecology;
Humans;
Leukopenia;
Nausea;
Obstetrics;
Ovarian Neoplasms*;
Paclitaxel;
Physical Examination;
Recurrence;
Thorax;
Thrombocytopenia;
Tomography, X-Ray Computed;
Vomiting
- From:Korean Journal of Gynecologic Oncology and Colposcopy
2001;12(2):120-127
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the efficacy and side effects of cispaltin and carboplatin each in combination with paclitaxel in recurrent epithelial ovarian cancer who had not taken paclitaxel-based chemotherapy. MATERIALS AND METHODS: Between January 1994 and October 1999, in department of obstetrics and gynecology, Asan medical Center, 42 recurrent ovarian cancer patients who had initial platinum-based chemotherapy except paclitaxel were treated with paclitaxel-based chemotherapy. One group was 14 patients treated with paclitaxel-cisplatin and the other group was 28 patients treated with paclitaxel-carboplatin. Disease free interval before recurrence was 6 months at least. Patients received paclitaxel 135mg/m2 followed by either cisplatin 75mg/m2 or carboplatin 300mg/m2. The schedule was repeated every 3 weeks for at least 6 cycle. Response was evaluated by physical examination, serial serum CA 125 measurement, chest PA before each cycle, and abdomino-pelvic CT scan every 3 cycles. RESULTS: As paclitaxel-cisplaitin group, with a median follow-up of 34.5 months (range, 9-60 months), 1 patient had complete response, 6 patients had partial response, 3 patients had stable disease and 4 patients had persistent disease, overall response rate was 50%, mean survival duration was 40 months. As paclitaxel-carboplatin group, with a median follow-up of 25.5 months (7-36 months), 4 patients had complete response, 11 patients had partial response, 6 patients had stable disease, and 7 patients had persistent disease, overall response rate was 53.4%, mean survival of 24 months. As grade of side effects in each group, we evaluated leukopenia, anemia, thrombocytopenia, nausea, vomiting, fever, neurological abnormality, and renal abnormality. The rate of grade 3 to 4 leukopenia was 11% in paclitaxel-cisplatin arm and 17% paclitaxel-arboplatin, in arm. CONCLUSION: These results demonstrate that the combined chemotherapy of paclitaxel followed by cisplatin or carboplatin is highly effective and safe in recurrent epithelial ovarian cancer who had taken no previous paclitaxel-based chemotherapy.
